The article presents the results of investigation of the impact of atopic dermatitis (AD) on the psychological state and social adaptation of patients. Different ways of AD treatment were discussed. Modern data on AD clinical course and its manifestations were presented. The objective of the research was to study the impact of AD on the quality of life in patients. The dermatology life quality index, assessment of situational and personal anxiety levels and degree of stress resistance in 45 patients with AD were offered and the necessity of this research has been proven. Patients with AD in the acute phase of the disease and a scoring atopic dermatitis (SCORAD) index of 40 – 90 were included into the study. The level of situational anxiety in patients with AD was (59.8 ± 1.16) points, and was significantly different from that of healthy individuals (43.7 ± 1.21) points, p <0.001. The level of personal anxiety in patients with AD was (79.8 ± 0.24) points and was significantly different from that of healthy individuals (54.6 ± 0.19), p <0.001. The degree of stress resistance in patients with AD was (293.4 ± 9.5) points while in healthy individuals it was (173.6 ± 19.9) points, p <0.001. Conclusion. Quality of life in AD patients is significantly worse than in healthy people. People with atopic dermatitis are physically and psychologically dependent on many factors of external and social environment, as even the smallest stimulus can trigger acute stage of the disease causing intense itching and psychological discomfort.
Allen B.R. Review of atopic dermatitis literature. Atopy reports: dermatitis and related disorders. 2001; 1(1): 7 - 9.
Ashcroft D.M., Dimmock P., Garside R., Stein K., Williams H.C. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials. BMJ. 2005; 330: 516.
Atherton D.J. Topical corticosteroids in atopic dermatitis. BMJ. 2003; 327: 942-943.
Bieber T. Atopic dermatitis. N Engl J Med. 2008; 358: 1483-1494.
Boguniewicz M. Topical treatment of atopic dermatitis. Immunol Allergy Clin N Am 24. 2004; 631-644.
Brenninkmeijer E.E., Schram M.E., Leeflang M.M., Bos J.D., Spuls P.I. Diagnostic criteria for atopic dermatitis: a systematic review. British Journal of Dermatology. 2008; 158(4): 754-765.
Callen J., Chamlin S., Eichenfield L.F., Ellis C., Girardi M., Goldfarb M. et al. A systematic review of the safety of topical therapies for atopic dermatitis. British Journal of Dermatology. 2007; 156(2): 203-221.
Carroll C.L., Balkrishnan R., Feldman S.R. et al. The burden of atopic dermatitis: impact on the patient, family, and society. Pediatr. Dermatol. 2005; 22: 192-199.
Charman C.R., Morris A.D., Williams H.C. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol 2000; 142: 931-936.
Eberlein B., Eicke C., Reinhardt H.W., Ring J. Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study). J Eur. Acad. Dermatol. Venereol. 2008; 22: 73-82.
Finlay A.Y. Quality of life in atopic dermatitis. J Am. Acad. Dermatol. 2001; 45(1): 64-66.
Hanifin J., Gupta A.K., Rajagopalan R., Parker C. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. British Journal of Dermatology. 2002; 147(3): 528-537.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.